Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in ...

(PDF) Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in ...

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML ... Background Mutations in the gene encoding isocitrate ...

Ivosidenib in IDH1-mutant, chemotherapy-refractory ... - The Lancet

Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively ...

Ivosidenib (CAS 1448347-49-6) - R&D Systems

Ivosidenib is a potent inhibitor of mutant isocitrate dehydrogenase enzyme 1 (mIDH1), with activity against a variety of mutant IDH1 enzymes.

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant ...

Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved for patients with IDH1 mutation and acute myeloid leukemia and previously ...

FDA approves ivosidenib for advanced or metastatic ...

On August 25, 2021, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, ...

Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in ... - Cureus

This review highlights the studies that have dealt with ivosidenib, an IDH1 inhibitor, in AML, the side effect profile, and the possible future ...

Isocitrate Dehydrogenase Inhibitor - an overview - ScienceDirect.com

Approximately 15%–20% of AML patients have IDH (IDH1 and IDH2) mutation, which causes abnormal maturation of myeloid cells (Stone, 2017). Several studies have ...

Full article: Ivosidenib, an IDH1 inhibitor, in a patient with recurrent ...

Strong interest in targeting IDH mutations has led to a variety of studies in both hematologic malignancies and solid tumors and to the approval of IDH ...

Safety and activity of ivosidenib in patients with IDH1-mutant ...

Isocitrate dehydrogenase-1 (IDH1) is mutated in up to 25% of cholangiocarcinomas, especially intrahepatic cholangiocarcinoma. Ivosidenib is ...

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an ...

Background Mutant isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) enzymes produce the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib ...

Ivosidenib in patients with IDH1 -mutant relapsed/refractory ...

... Background: Mutations in isocitrate dehydrogenase 1 ( IDH1) occur in ... Ivosidenib (IVO), an oral, potent, targeted inhibitor of the mutant ...

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

Ivosidenib (AG-120), an IDH1 inhibitor, was tested in IDH1-mutant (mIDH1) solid tumors including glioma in a multicenter, open-label, phase I clinical study [51] ...

The IDH1 Inhibitor Ivosidenib May Slow IDH1-Mutant Glioma ...

Ivosidenib, an inhibitor of mutant IDH1, was safe and showed early evidence of efficacy in glioma.

Preclinical Drug Metabolism, Pharmacokinetic, and ...

Ivosidenib is a once daily (QD), orally available, potent, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for the treatment of patients with ...

IDH Inhibitor Ivosidenib Improves Overall Survival in Previously ...

Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months compared with placebo in ...

IVOSIDENIB - Inxight Drugs

Ivosidenib (AG-120) is an inhibitor of isocitrate dehydrogenase 1 (IDH1) This experimental drug inhibits mutant IDH1, leading to increased differentiation ...

Paper: Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase ...

Patients (pts) with relapsed/refractory (R/R) myelodysplastic syndromes (MDS) have a poor prognosis and, until recently, lacked therapeutic options. Ivosidenib ...

FDA Approves Ivosidenib Tablets for IDH1-Mutant ...

The FDA has approved ivosidenib Tablets (Tibsovo) for the treatment of patients with IDH1-mutant cholangiocarcinoma, as detected by an FDA approved test.

Ivosidenib Extends Survival in Patients with Cholangiocarcinoma ...

... inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced ...

Annotation of FDA Label for ivosidenib and IDH1 - PharmGKB

Ivosidenib is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. ... The most common of such mutations are R132H and ...